- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07943377
Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)
A Phase 1 Trial in Healthy Participants to Evaluate Single and Multiple Oral Dose Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)
A Phase 1 trial of ALG-000184 in healthy participants to assess the safety and tolerability of single and multiple (if applicable) oral doses of ALG-000184 (Part A and B) and ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Aligos Therapeutics
- Telefonnummer: 800-466-6059
- E-post: info@aligos.com
Studieorter
-
-
Wisconsin
-
Madison, Wisconsin, Förenta staterna, 53704
- Aligos Investigational Site
-
Kontakt:
- Aligos Investigational Site
- Telefonnummer: 800-466-6059
- E-post: info@aligos.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria: Key Inclusion Criteria
- Parts A and B only: Male or female between 18 and 60 years of age
- Part C only: Males between 18 and 55 years of age.
- Body mass index between 18.0 kg/m2 and 32.0 kg/m2
- In good health, as determined by no clinically significant findings from medical history, 12-lead ECG and vital signs measurements, and clinical laboratory assessments.
- Part C only: History of a minimum of 1 bowel movement per day.
Exclusion Criteria: Key Exclusion Criteria:
-
Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
-
History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator (or designee).
-
History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs.
-
Confirmed systolic blood pressure >140 or <90 mmHg, diastolic blood pressure >90 or <50 mmHg, or pulse rate >100 or <40 beats per minute.
-
Positive hepatitis panel and/or positive human immunodeficiency virus test.
-
Parts A and B only: Any of the following at screening or check-in:
- QTcF >450 ms in males or >470 ms in females
- QRS duration >120 ms
- PR interval >210 ms
- findings which would make QTc measurements difficult or QTc data uninterpretable
-
Administration of any vaccine within 30 days prior to dosing.
-
Use or intend to use any prescription medications/products, other than hormone replacement therapy, within 14 days prior to dosing
-
Alcohol consumption of >21 units per week for males and >14 units per week for females, as applicable.
-
Positive urine drug screen at screening or positive alcohol test result or positive urine drug screen at check-in.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: ALG-000184
Oral tablet(s) of placebo in HV participants once daily for up to 10 days |
Single or multiple doses of ALG-000184 |
|
Placebo-jämförare: Placebo
Oral tablet(s) of placebo in HV participants once daily for up to 10 days |
Single or multiple doses of Placebo |
|
Övrig: [14C]ALG-000184
|
Single oral dose of [14C]ALG-000184 Single micodose of [13C7,15N1]ALG-001075 with combination of [14C]ALG-000184 |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Safety and Tolerability (Part A and B)
Tidsram: From enrollment to end of treatment at 10 days
|
Number of participants with Incidence and severity of adverse events, 12-lead electrocardiogram parameters, and abnormal clinical laboratory results |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Tidsram: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including AUC0-∞ |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Tidsram: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including AUC0-tlast |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Tidsram: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including AUC0-τ |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Tidsram: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including Cmax |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Tidsram: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including tmax t1/2 |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Tidsram: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including ARAUC |
From enrollment to end of treatment at 10 days
|
|
Total radioactivity recovery (fet1-t2) in urine and feces (Part C)
Tidsram: From enrollment to end of treatment at 10 days
|
determine the routes, rates of elimination, and mass balance of total radioactivity following a single oral dose of [14C]ALG-000184 |
From enrollment to end of treatment at 10 days
|
|
Metabolic profiles of ALG-000184 (Part C)
Tidsram: From enrollment to end of treatment at 10 days
|
Determine, where possible, the metabolite profiles in plasma, urine, and feces following administration of [14C]ALG-000184 |
From enrollment to end of treatment at 10 days
|
|
Identification of ALG-000184 (Part C)
Tidsram: From enrollment to end of treatment at 10 days
|
Determine, where possible, the chemical structure of major metabolites in plasma, urine, and feces following administration of [14C]ALG-000184 |
From enrollment to end of treatment at 10 days
|
|
Bioavailability of ALG-001075 (Part C)
Tidsram: From enrollment to end of treatment at 10 days
|
Determine the absolute bioavailability of ALG-001075 following oral administration of [14C]ALG-000184 relative to IV administration of [13C7,15N1]ALG-001075 |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Tidsram: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including AUC0-∞ |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Tidsram: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including AUC0-tlast |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Tidsram: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including Cmax |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Tidsram: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including tmax |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Tidsram: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including t1/2 |
From enrollment to end of treatment at 10 days
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
QTc (Part A and B)
Tidsram: From enrollment to end of treatment at 10 days
|
Evaluate the effect of single and multiple (if applicable) oral doses of ALG-000184 on QTc in healthy participants |
From enrollment to end of treatment at 10 days
|
|
Safety and Tolerability (Part C)
Tidsram: From enrollment to end of treatment at 10 days
|
Number of participants with Incidence and severity of adverse events, 12-lead electrocardiogram parameters, and abnormal clinical laboratory results |
From enrollment to end of treatment at 10 days
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- ALG-000184-209
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .